Skip to main content

Table 3 Summary of previous studies on etoposide/cisplatin- or irinotecan/cisplatin-based concurrent chemoradiotherapy for limited-disease small-cell lung cancer

From: Efficacy of concurrent chemoradiotherapy for patients with limited-disease small-cell lung cancer: a retrospective, nationwide, population-based cohort study

Author Phase No. of patients Regimen Radiation dose RR (%) PFS (m), P-value OS (m), P-value Grade 3/4 toxicity (%)
Faivre-Finn [4] (2017) III 247 EP-CCRT BID vs. QD 45 Gy vs. 66 Gy   15.4 vs. 13.4; HR = 1.12; p = 0. 26 30 vs. 25; HR = 1.18, p = 0·14; 2 year SR (56% vs. 51%) Neutropenia (74% vs. 65%) Esophagitis (19% vs. 19%) Radiation pneumonitis (3% vs. 2%)
Kubota [12] (2014) III 281 EP-CCRT BID followed by IP vs. EP 45 Gy   12 vs. 13.2; HR 1.10; p = 0.74 33.6 vs. 38.4; HR = 1·09, p = 0·70; 5-year SR (33.7% vs. 35.8%) Neutropenia (95% vs. 78%) Anemia (35% vs. 50%) Diarrhea (2% vs. 1%)
Fukuda [11] (2012) II 34 IP-CCRT 50 Gy 100 14.3 44.5; 2- and 5-year SR (66.7, 46.1%) Neutropenia 38%; Pneumonitis 6% Diarrhea 3%; Esophagitis 0%
Naidu [10] (2014) II 36 IP-CCRT BID 45–54 Gy 67   19; 1-, 2-, 3-year SR (60, 44, 30%) Symptomatic pneumonitis 0% Symptomatic esophagitis 13%
Saito [14] (2006) II 51 EP-CCRT BID followed by IP 45 Gy 88 11.8 23; 2- and 3-year SR (49, 29.7%) Neutropenia 88%; Infection 33% Electrolyte imbalance 20% Diarrhea 14%
Jeong [20] (2006) II 20 IP-CCRT 50.4 Gy 85 12 20; 1- and 2-year SR (85, 35%) Neutropenia 60%; Anemia (20%) Nausea/vomit(55%); Diarrhea (35%)
Hong [13] (2011) II 19 IP-CCRT QD 54 Gy 89.5 7.6 12.4; 2-year SR (75.0%) Radiation-induced pneumonitis 53% Neutropenia 32%
Sohn [8] (2007) II 33 IP-CCRT BID 45–54 Gy 87.9 14.4 26.1; 2-year SR (54.9%) Neutropenia 81.8%; Diarrhea 21.2% Radiation pneumonitis 9.1%
Han [15] (2005) II 33 IP followed by EP-CCRT BID 45 Gy 97 12.9 25; 1- and 2-year SR (85.7, 53.9%) Neutropenia (68% + 100%)a, Febrile neutropenia (20% + 60%)b
  1. RR, response rate; PFS, progression-free survival; OS, overall survival; EP, etoposide/platinum; IP, irinotecan/platinum; CCRT, concurrent chemoradiotherapy; BID, bis in die (twice a day); QD, quaque die (once a day); HR, hazard ratio; SR, survival rate
  2. aGrade 3 or 4 neutropenia occurred during induction chemotherapy in 68% patients and during CCRT in 100% patients
  3. bGrade 3 or 4 febrile neutropenia occurred during induction chemotherapy in 20% patients and during CCRT in 60% patients